This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Future Growth

Future criteria checks 2/6

9 Meters Biopharma is forecasted to grow earnings and revenue by 41.4% and 56.6% per annum respectively. EPS is expected to grow by 39.9%. Return on equity is forecast to be -185.6% in 3 years.

Key information

41.4%

Earnings growth rate

39.9%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	56.6%
Future return on equity	-185.6%
Analyst coverage	Low
Last updated	30 May 2023

Recent future growth updates

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

Earnings and Revenue Growth Forecasts

NasdaqCM:NMTR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-43	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	3
12/31/2023	3	-43	N/A	N/A	4
3/31/2023	N/A	-46	-37	-37	N/A
12/31/2022	N/A	-44	-37	-37	N/A
9/30/2022	N/A	-41	-35	-35	N/A
6/30/2022	N/A	-46	-36	-34	N/A
3/31/2022	N/A	-43	-36	-33	N/A
12/31/2021	N/A	-37	-32	-29	N/A
9/30/2021	N/A	-32	-30	-28	N/A
6/30/2021	N/A	-27	-24	-24	N/A
3/31/2021	N/A	-63	-26	-23	N/A
12/31/2020	N/A	-61	-23	-19	N/A
9/30/2020	N/A	-65	-19	-16	N/A
6/30/2020	N/A	-66	-19	-16	N/A
3/31/2020	N/A	-26	-16	-16	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-22	-17	-17	N/A
6/30/2019	N/A	-14	-17	-17	N/A
3/31/2019	N/A	-14	-12	-12	N/A
12/31/2018	N/A	-24	-15	-15	N/A
9/30/2018	N/A	-22	-15	-15	N/A
6/30/2018	N/A	-24	-12	-12	N/A
3/31/2018	N/A	-23	-11	-11	N/A
12/31/2017	N/A	-12	-5	-5	N/A
9/30/2017	N/A	-11	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NMTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NMTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NMTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NMTR's revenue (56.6% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: NMTR's revenue (56.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NMTR is forecast to be unprofitable in 3 years.

This company listing is no longer active

9 Meters Biopharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

Price target decreased to US$57.00

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies